Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Study Summary

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Conditions

Renal Cell Carcinoma Urothelial Carcinoma Castration-resistant Prostate Cancer

Interventions / Drugs

DCC-2812

View on ClinicalTrials.gov ↗

Sponsor

DCPH

Deciphera Pharmaceuticals

Oncology

D40/100

Study Details

Enrollment60 participants

Primary Completion—

Lead SponsorDeciphera Pharmaceuticals, LLC

Data Retrieved2026-04-11 04:11:28.433252+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.